The Department of Pediatric Hematology and Oncology (TAO) of AGHIA SOPHIA CHILDREN’S HOSPITAL, Athens, Greece, is located in the wing of "Aghia Sophia" Children's Hospital, named Children’s Oncology Unit “Marianna V. Vardinoyannis-ELPIDA".
“Aghia Sophia” Children’s Hospital is the largest pediatric Hospital in Greece hosting 750 patient beds, a tertiary dedicated pediatric hospital. The Hospital provides a multidisciplinary, integrated health care for children, which includes all pediatric subspecialties. Three hundred children are diagnosed every year with cancer in Greece. The Department pioneers for more than 35 years, in providing state of the art care, to children with cancer from all over Greece. Since 1980, more than 4000 children had been diagnosed, managed and followed in TAO.
“Aghia Sophia” Children’s Hospital has participated to the Joint Action on Rare Cancers (JARC) European Programme and presently participates to the Joint Accreditation Committee ISCT-Europe & EBMT (JACIE), PARTN-ER and HARMONY (Healthcare Alliance for Resourceful Medicines Oﬀensive against Neoplasms in Hematology), conect4children, PanCareFollowUp and other projects of SIOP-Europe. "Aghia Sophia" Children's Hospital has been accredited with the National Designation for Rare and Complex Disease Reference Center in Pediatric Hematology and Oncology, and recently has applied for 3 European Reference Networks (ERN), PAEDCAN (referred to pediatric cancer), EUROBLOODNET (referred to rare blood cell diseases)and GENTURIS( referred to rare genetic diseases predisposing to cancer).
The Department of Pediatric Hematology and Oncology (TAO) of AGHIA SOPHIA CHILDREN’S HOSPITAL, employs Inpatient, Outpatient and Day Care Clinics and has 28 inpatient beds and 8 day-care beds. TAO also runs a dedicated specialized Hematology Lab, which performs routine hematological examinations, as well as cytochemistry, semi-solid cell cultures from bone marrow progenitor cells, molecular diagnostics and biobanking.
We collaborate closely with all Departments of our Hospital, i.e. Hematopathology and Surgical Pathology, Nuclear Medicine (therapeutic MIBG), and pediatric Bone Marrow Transplantation Unit (JACIE accredited), as well as the Department of Pediatric Radiotherapy (P&A Kyriakou Children's Hospital), etc.
Apart from oﬀering highly specialized clinical service, we perform research and academic training for hematologists, pediatricians, nurses and other relative health care professionals. We provide healthcare services for hundreds of patients covering all the spectrum of malignant neoplastic diseases in childhood with a special interest in ALL, AML, MDS, and solid tumors.
We are investing in the full spectrum of Pediatric Hematology and Oncology with special interest in leukemias, MDS/JMML,SAA, BMFS, lymphomas, neuroblastoma, brain tumors, Histiocytosis, early and late toxicity effects, and other solid tumors, as well as benign hematology .
Members of the Department’s team are active members of the SIOPE, SIOP, SIOPEN, EHA, BFM, Histiocytosis Society, the Hellenic Society of Hematology and the Hellenic Society of Pediatric Hematology and Oncology (HESPHO). The Head of the Department and members of the team are national representatives in the Cooperative Trials and Boards at a European and International level i.e. ALLIC-BFM, ALLIC-Relapse, EWOG-MDS/JMML/SAA, AML, SIOPEN High Risk and Low and Intemediate Risk Protocols, the European Consortium for Histiocytosis, and Histiocytosis Society.
Dr. Sophia Polychronopoulou, Head of the Department, will host the 9th International Symposium on MDS and SAA in Childhood on October 1-3, 2020 in Athens and Dr. Vassilios Papadakis through HESPHO, will host the Annual General Meeting of SIOPEN (Europe Neuroblastoma).
TAO has been recently accredited with the designation of Rare and Complex Disease Reference Center in Rare Blood Disorders (Aplastic anemia, inherited bone marrow failure syndromes and Histiocytosis), in Genetic Predisposition (neurofibromatosis, MDS/JMML with genetic predisposition and other genetic conditions with malignancy potential and primary immune deficiencies with malignant potential), and in Pediatric Hematology and Oncology, jointly with the University Unit of Hematology/Oncology of First Department of Pediatrics.
Healthcare professionals in the multidisciplinary team and area of expertise
1.Sophia Polychronopoulou, MD, PhD, Head of the Department
National Representative for ALL (ALLIC-BFM)
National Representative for ALL relapse (ALLIC-Relapse Guidance Steering Committee)
National Representative for AML
National Representative EWOG-MDS/JMML/SAA
2. Vassilios Papadakis, MD, PhD,
National Representative for Neuroblastoma and Histiocytosis,
3.Sophia Papargyri, MD ( inpatient and out patient clinical service)
4.Charikleia Kelaidi MD, PhD, (AML, MDS/JMML/SAA, Genetic Predisposition)
5.Mirella Ampatzidou , MD, PhD, (ALL, ALL relapse, CML, thromboses)
6.Kondilia Antoniadi , MD (Kidney tumors, cardiotoxicity, infections)
7.Vasiliki Tzotzola, MD (Histiocytosis, Sarcomas, Brain Tumors, late effects)
8. Vassileios Dendrinos, MD
9.Loizos Petrikkos , MD, PhD, (MDS/JMML/SAA, Histiocytosis, infections)
Ms. Sophia Vasila, Head of Nurses, Nursing Staff of 19 Nurses specialized in Pediatric Hematology and Oncology
Mr. Konstantinos Tsitsikas, Biologist
Ms. Efie Gkinopoulou, Laboratory Technician
Ms. Maria Klonou, Clinical Social Worker
Ms. Ellie Metaxa, Psychologist
Ms. Evaggelia Stefanopoulou, Secretary
Healthcare Indexes: Patient Outcomes
Acute lymphoblastic leukemia (2002-2014): 5-year overall survival 90%, number of allogeneic transplants 32.
Acute myeloid leukemia (2000-2019): 5-year overall survival 68% number of allogeneic transplants 17.
Fanconi anemia (2000-2019): 5-year overall survival 71% number of allogeneic transplants 9.
Lymphomas (2000-2019): 5-year overall survival 90%, number of allogeneic transplants 1.
Histiocytosis syndromes (2000-2019): 5-year overall survival 98%.
Brain tumors (2000-2019): 5-year overall survival 52%.
Bone tumours (2000-2019): 5-year overall survival 77%.
Sarcomas (2000-2019): 5-year overall survival 70%.
Neuroblastoma (2000-2019): 5-year overall survival 73%.
Kidney tumours (2000-2019): 5-year overall survival 98%.
Liver tumours (2000-2019): 5-year overall survival 45%.
Total number of allogeneic HCT for hematological diseases (2000-2019): 206
''Sophia Polychronopoulou, MD,PhD, Pediatric Hematologist-Oncologist,
Head of the Department of Pediatric Hematology-Oncology (T.A.O.),
Head of the Oncology Committee and the Medical Service, AGHIA SOPHIA Children’s Hospital,
Thivon & Papadiamantopoulou, Goudi, GR-11527, Athens, Greece''